Skip to main content

Table 4 Impact of ATG4B expression levels on disease-free survival by the different demographic and clinicopathologic factors with colorectal cancer

From: ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer

Variable

 

No. (%)

CHR (95% CI)

p value*

AHR (95% CI)

p value †

Sex

      

 Female

Low

25 (53.5)

1.00

 

1.00

 

High

22 (46.5)

1.70 (0.76–3.84)

0.199

3.18 (1.30–7.80)

0.012 a

 Male

Low

38 (53.2)

1.00

 

1.00

 

High

33 (46.8)

2.79 (1.41–5.54)

0.003

6.78 (2.89–15.88)

< 0.001 a

Age, yrs

      

 ≦ 60

Low

22 (48.9)

1.00

 

1.00

 

High

23 (51.1)

2.01 (0.87–4.61)

0.102

3.55 (1.41–8.94)

0.007 a

 >60

Low

41 (56.2)

1.00

 

1.00

 

High

32 (43.8)

2.51 (1.28–4.92)

0.007

5.62 (2.50-12.66)

< 0.001 a

Cell differentiation

      

 Well

Low

3 (68.0)

1.00

 

1.00

 

High

1 (32.0)

434.45 (0.00-8.954E + 12)

0.616

434.45 (0.00-8.954E + 12)

0.616b

 Moderate, poor

Low

60 (44.1)

1.00

 

1.00

 

High

54 (55.9)

2.24 (1.31–3.81)

0.003

5.17 (2.80–9.54)

< 0.001 b

AJCC pathological stage

      

 I, II

Low

12 (57.1)

1.00

 

1.00

 

High

9 (42.9)

3.11 (1.03–9.38)

0.044

3.60 (1.04–12.46)

0.043 c

 III, IV

Low

51 (52.6)

1.00

 

1.00

 

High

46 (47.4)

4.41 (2.24–8.68)

< 0.001

4.37 (2.21–8.65)

< 0.001 c

T classification

      

 T1, T2

Low

12 (57.1)

1.00

 

1.00

 

High

9 (42.9)

3.22 (0.59–17.64)

0.178

5.50 (0.61–49.32)

0.128d

 T3, T4

Low

51 (52.6)

1.00

 

1.00

 

High

46 (47.4)

2.18 (1.26–3.78)

0.005

3.73 (2.00-6.98)

< 0.001 d

N classification

      

 N0

Low

27 (42.2)

1.00

 

1.00

 

High

37 (57.8)

2.33 (0.98–5.56)

0.056

2.18 (0.86–5.53)

0.102e

 N1, N2

Low

36 (66.7)

1.00

 

1.00

 

High

18 (33.3)

4.75 (2.29–9.86)

< 0.001

4.69 (2.24–9.80)

< 0.001 e

Postoperative RT

      

 No

Low

56 (50.9)

1.00

 

1.00

 

High

54 (49.1)

2.32 (1.34–4.02)

0.003

4.67 (2.53–8.64)

< 0.001 a

 Yes

Low

7 (87.5)

1.00

 

1.00

 

High

1 (12.5)

2.96 (0.27–32.84)

0.376

2.96 (0.27–32.84)

0.376a

  1. Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; RT, radiotherapy.
  2. *p values were estimated by Cox’s regression.
  3. † p values were estimated by multivariate Cox’s regression.
  4. a Adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II).
  5. b Adjusted for AJCC pathological stage (stage III + IV vs. stage I + II).
  6. c Adjusted for cell differentiation (moderate + poor vs. well).
  7. d Adjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs. N0).
  8. e Adjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs. T1 + T2).